Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies

Inclusion Criteria: * Karnofsky Performance Status (KPS) \> 70%. * Histologically-confirmed advanced malignancy for which a standard, approved therapy is not available. * Adequate renal, liver, pancreatic and hematologic function * Signed informed consent (sample IC form is provided in Appendix A). Exclusion Criteria * Administration of chemotherapy, biological, immunotherapy or investigational agent (therapeutic or diagnostic) within 28 days * Patients that require G-CSF and/or platelet support during screening and are likely to require G-CSF and/or platelet support for the duration of the clinical trial. * Patients with ongoing coagulopathies and/or taking anticoagulants * Patients receiving intrathecal therapy. * Known brain metastases. * Pre-existing adrenal insufficiency; concomitant therapy with replacement corticosteroids. Pre-existing acute or chronic pancreatitis. * Significant cardiac disease. * Pregnant or breast-feeding women. * Concurrent, active secondary malignancy for which the patient is receiving therapy. (Lymphoma patients with a diagnosis of a potentially hormone-sensitive tumor who are without evidence of disease for this second malignancy may continue to receive hormonal therapy). * Patients with proteinuria Grade 2 or greater * Active uncontrolled bacterial or fungal infection requiring systemic therapy; infection requiring parenteral antibiotics. * Patients who are known to be HIV positive or have active Hepatitis A, B, or C infection.